Dominic S Ng Selected Research

Lecithin Cholesterol Acyltransferase Deficiency (Lecithin:Cholesterol Acyltransferase Deficiency)

1/2018	Novel metabolic phenotypes in lecithin cholesterol acyltyransferase-deficient mice.
12/2015	Lecithin:Cholesterol Acyltransferase (LCAT) Deficiency Promotes Differentiation of Satellite Cells to Brown Adipocytes in a Cholesterol-dependent Manner.
1/2013	Lecithin cholesterol acyltransferase deficiency protects from diet-induced insulin resistance and obesity--novel insights from mouse models.
6/2012	Lecithin:cholesterol acyltransferase deficiency protects against cholesterol-induced hepatic endoplasmic reticulum stress in mice.
5/2011	Lecithin cholesterol acyltransferase null mice are protected from diet-induced obesity and insulin resistance in a gender-specific manner through multiple pathways.
8/2007	LCAT-null mice develop improved hepatic insulin sensitivity through altered regulation of transcription factors and suppressors of cytokine signaling.
1/2006	Coordinated alteration of hepatic gene expression in fatty acid and triglyceride synthesis in LCAT-null mice is associated with altered PUFA metabolism.
10/2004	A novel in vivo lecithin-cholesterol acyltransferase (LCAT)-deficient mouse expressing predominantly LpX is associated with spontaneous glomerulopathy.
4/2002	Oxidative stress is markedly elevated in lecithin:cholesterol acyltransferase-deficient mice and is paradoxically reversed in the apolipoprotein E knockout background in association with a reduction in atherosclerosis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Dominic S Ng Research Topics

Disease

9	Lecithin Cholesterol Acyltransferase Deficiency (Lecithin:Cholesterol Acyltransferase Deficiency) 01/2018 - 04/2002
6	Obesity 01/2018 - 05/2011
5	Insulin Resistance 01/2018 - 08/2007
4	Atherosclerosis 01/2020 - 04/2002
3	Non-alcoholic Fatty Liver Disease 01/2020 - 06/2013
3	Cardiovascular Diseases (Cardiovascular Disease) 12/2014 - 04/2005
3	Hypertriglyceridemia 08/2007 - 02/2004
2	Heart Diseases (Heart Disease) 01/2020 - 01/2013
2	Hyperlipidemias (Hyperlipidemia) 10/2013 - 07/2008
2	Coronary Disease (Coronary Heart Disease) 08/2004 - 04/2002
1	Alcoholic Fatty Liver 07/2016
1	Dyslipidemias (Dyslipidemia) 10/2013
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2013
1	Inflammation (Inflammations) 07/2008
1	Renal Insufficiency (Renal Failure) 10/2004
1	Vascular Ring 04/2002
1	Hypoalphalipoproteinemias (Hypoalphalipoproteinemia) 04/2002

Drug/Important Bio-Agent (IBA)

7	Phosphatidylcholine-Sterol O-Acyltransferase (Lecithin Cholesterol Acyltransferase)IBA 12/2015 - 04/2002
6	CholesterolIBA 01/2020 - 06/2012
6	HDL CholesterolIBA 12/2014 - 08/2004
4	LDL Receptors (LDL Receptor)IBA 01/2018 - 05/2011
4	Insulin (Novolin)FDA Link 10/2013 - 08/2007
4	Triglycerides (Triacylglycerol)IBA 01/2013 - 02/2004
2	InflammasomesIBA 01/2018 - 07/2016
2	Sucrose (Saccharose)IBA 07/2016 - 05/2011
2	Glucose (Dextrose)FDA LinkGeneric 01/2013 - 02/2004
1	EnzymesIBA 01/2020
1	Lipoproteins (Lipoprotein)IBA 01/2018
1	LecithinsIBA 01/2018
1	oxidized low density lipoproteinIBA 10/2013
1	ChylomicronsIBA 10/2013
1	VLDL LipoproteinsIBA 10/2013
1	LipidsIBA 01/2013
1	Aryldialkylphosphatase (Paraoxonase)IBA 07/2008
1	CytokinesIBA 08/2007
1	Transcription Factors (Transcription Factor)IBA 08/2007
1	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 04/2005
1	HDL LipoproteinsIBA 10/2004
1	Apolipoproteins E (ApoE)IBA 04/2002
1	ApolipoproteinsIBA 04/2002
1	Phospholipids (Phosphatides)FDA LinkGeneric 04/2002
1	F2-Isoprostanes (F2 Isoprostanes)IBA 04/2002
1	Superoxides (Superoxide)IBA 04/2002